Dr William Parker

All publications

Journal articles

• Elamin N, Nelson T, Parker W, Varian F, Williamson G, McMellon H, Hanson J, Middle J, Bridge C, Judge HM , Briffa N et al (2022) THROMBOINFLAMMATORY RESPONSE TO ON-PUMP CORONARY ARTERY BYPASS GRAFT SURGERY LEADS TO IMPAIRED PLATELET REACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology, 79(9), 1094-1094.
• Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, Duerschmied D, Smyth SS, Parker WAE, Ajjan RA , Vilahur G et al (2022) Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology.
• Parker WAE, Sagar R, Kurdee Z, Hawkins F, Naseem KM, Grant PJ, Storey RF & Ajjan RA (2021) A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes : role of dosing and glycaemic control. Cardiovascular Diabetology, 20(1).
• Parker WAE & Storey RF (2021) Ticagrelor monotherapy in CKD: better safety at what price?. Eur Heart J.
• Sanderson NC, Parker WAE & Storey RF (2021) Ticagrelor : clinical development and future potential. Reviews in Cardiovascular Medicine, 22(2), 373-394. View this article in WRRO
• Nelson TA, Parker WAE, Ghukasyan Lakic T, Westerbergh J, James SK, Siegbahn A, Becker RC, Himmelmann A, Wallentin L & Storey RF (2021) Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy.. Platelets, 1-7.
• Giustozzi M, Ehrlinder H, Bongiovanni D, Borovac JA, Guerreiro RA, Gąsecka A, Papakonstantinou PE & Parker WAE (2021) Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment. Blood Reviews, 100864-100864.
• Gąsecka A, Borovac JA, Guerreiro RA, Giustozzi M, Parker W, Caldeira D & Chiva-Blanch G (2021) Thrombotic complications in patients with COVID-19 : pathophysiological mechanisms, diagnosis, and treatment. Cardiovascular Drugs and Therapy, 35(2), 215-229.
• Parker WAE & Storey RF (2021) Platelets and the endothelium: active participants in severe COVID-19 infection. JACC: Basic to Translational Science, 6(3), 219-221.
• Hennigan BW, Good R, Adamson C, Parker WAE, Martin L, Anderson L, Campbell M, Serruys PW, Storey RF & Oldroyd KG (2020) Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention : a GLOBAL LEADERS substudy. Platelets. View this article in WRRO
• Parker WAE, Gorog DA, Geisler T, Vilahur G, Sibbing D, Rocca B & Storey RF (2020) Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. European Heart Journal Supplements, 22(Supplement_M), M26-M34.
• Parker WAE, Schulte C, Barwari T, Phoenix F, Pearson SM, Mayr M, Grant PJ, Storey RF & Ajjan RA (2020) Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus : a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular Diabetology, 19(1). View this article in WRRO
• Parker WAE, Parker VL, Parker G & Parker AJ (2020) Acoustic shock: an update review. The Journal of Laryngology & Otology, 134(10), 848-853.
• Ow KW, Parker W, Onwordi E & Storey RF (2020) 51 Adherence to cardiologist recommendations regarding extended duration of ticagrelor for patients undergoing PCI for myocardial infarction. Heart, 106(Suppl 2), a41-a41.
• Parker WAE (2020) Glimpsing Into the miRe of Ischemia Reperfusion Injury. Transplantation, 104(9), 1769-1771.
• Parker WAE & Storey RF (2020) Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist. Expert Opinion on Emerging Drugs. View this article in WRRO
• Storey RF & Parker WAE (2020) Opiates and Clopidogrel Efficacy. Journal of the American College of Cardiology, 75(3), 301-303.
• Parker W & Iqbal J (2020) Comparison of Contemporary Drug-eluting Coronary Stents – Is Any Stent Better than the Others?. Heart International, 14(1), 34-34.
• Parker WAE & Storey RF (2019) Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
• Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B , Judge HM et al (2019) Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
• Parker WAE, Eriksson N, Becker RC, Voora D, Åkerblom A, Himmelmann A, James SK, Wallentin L & Storey RF (2019) Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 30(5), 579-588.
• Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED , Wheeldon NM et al (2018) Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
• Sumaya W, Parker W, Fretwell R, Hall I, Barmby D, Richardson J, Iqbal J, Adam Z, Morgan K, Gunn J , Mason A et al (2018) Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
• Parker WAE, Sinha A, Ramshaw HJ, D’Arcy EK, Braidley PC & Al-Mohammad A (2018) Secondhand Hypertrophy. Transplantation, 102(9), e397-e398.
• Onwordi ENC, Parker WAE & Storey RF (2018) Dual antiplatelet therapy in the ‘real world’. Heart, 104(19), 1555-1556.
• Parker WAE, Edafe O & Balasubramanian SP (2017) Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature. Pragmatic and Observational Research, 8, 57-67. View this article in WRRO
• Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Michael Gibson C , White HD et al (2017) Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 117(06), 1093-1100.
• Parker WAE & Storey RF (2016) Ticagrelor: agonising over its mechanisms of action. Blood, 128(23), 2595-2597.
• Storey RF & Parker WAE (2016) Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 134(11), 793-796. View this article in WRRO
• Parker WAE & Storey RF (2016) Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 102(10), 783-789.
• Parker W, Parker V, Parker G & Parker A (2014) ‘Acoustic shock’: A new occupational disease? Observations from clinical and medico-legal practice. International Journal of Audiology, 53(10), 764-769.
• Parker WAE & Parker AJ (2009) Cystic swellings of the neck. Surgery (Oxford), 27(12), 530-534.
• Maguire JJ, Parker WAE, Foord SM, Bonner TI, Neubig RR & Davenport AP (2009) International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacological Reviews, 61(1), 1-8.
• Parker WAE & Storey RF () Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?. Cardiovascular Research.
• Papakonstantinou PE, Borovac JA, Gąsecka A, Bongiovanni D, Ehrlinder H, Giustozzi M, Parker WAE & Guerreiro RA () Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?. European Journal of Preventive Cardiology.
• Parker WAE & Storey RF () Antithrombotic therapy for patients with chronic coronary syndromes. Heart.
• Parker WAE () Aspirin after PCI: in the twilight of its years?. Platelets, 1-3.
• Parker VL, Parker WAE, Davies HM, Ramshaw HJ, D’Arcy EK, Al-Mohammad A, Mateszko O, Kew FM & Braidley PC () Benefits and Challenges of Robotic Pelvic Surgery in a Cardiac Transplant Recipient. Surgical Innovation, 155335062093600-155335062093600.
• Parker WAE & Storey RF () Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets, 1-8.
• Ow KW, Parker WAE, Porter MM, Hanson J, Judge HM, Briffa NP, Thomas MR & Storey RF () Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets, 1-7.
• Parker WAE & Storey RF () Choosing a perspective on mortality with DAPT. European Heart Journal, ehv610-ehv610.
• Sumaya W, Parker WAE, Judge HM, Hall IR, Orme RC, Adam Z, Richardson JD, Rothman AMK, Morgan KP, Gunn JP & Storey RF () Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets. View this article in WRRO
• Zwart B, Parker WAE & Storey RF () New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of Clinical Medicine, 9(7), 2059-2059.
• Parker VL, Winter MC, Whitby E, Parker WAE, Palmer JE, Tidy JA, Pacey AA, Hancock BW & Harrison RF () Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia. British Journal of Cancer.

Chapters

• Parker W & Storey R (2018) Acute coronary syndromes: Thrombotic Response

Conference proceedings papers

• Parker W, Gosling R, Churton A, Parviz Y, Iqbal J, Heppenstall J, Teare D & Gunn J (2018) P28 DOES MILD CORONARY ARTERY ATHEROSCLEROSIS PROGRESS AT SERIAL ANGIOGRAPHY?. Cardiovascular Research, Vol. 114(suppl_2) (pp S9-S9)
• Parker WA, Ramshaw HJ, D'arcy EK, Pickering J, Burger RR, Adatia K, Ogunleye O, Ow KW, Armour SJ, Girach AA , Braidley PC et al (2018) Does deactivation of a site's surgical cardiac transplant program affect the long-term survival of its recipients?. EUROPEAN JOURNAL OF HEART FAILURE, Vol. 20 (pp 447-447)
• Parker W, Orme RC, Sumaya W, Hanson J, Stokes H, McMellon H, Shaw P, Judge H & Storey R (2018) ULTRA-LOW-DOSE TWICE-DAILY ASPIRIN IMPROVES HEMOSTASIS AND MAINTAINS PLATELET INHIBITION IN ACUTE CORONARY SYNDROME PATIENTS RECEIVING TICAGRELOR. Journal of the American College of Cardiology, Vol. 71(11) (pp A30-A30)
• Weng Ow K, Thomas M, Parker W, Judge H & Storey R (2017) 72 Offset of ticagrelor prior to coronary artery bypass graft surgery (cabg) surgery. Heart, Vol. 103(Suppl 5) (pp A53.2-A54)